A5064337321- Migraine and Headache Studies
- Trigeminal Neuralgia and Treatments
- Sympathectomy and Hyperhidrosis Treatments
- Psychosomatic Disorders and Their Treatments
- Body Image and Dysmorphia Studies
- Neuroscience of respiration and sleep
- Neuropeptides and Animal Physiology
- Cardiovascular Syncope and Autonomic Disorders
- Breastfeeding Practices and Influences
- Health Literacy and Information Accessibility
- Respiratory and Cough-Related Research
- Ophthalmology and Eye Disorders
- Maternal Mental Health During Pregnancy and Postpartum
- Olfactory and Sensory Function Studies
- Neurological Disorders and Treatments
- Sexual function and dysfunction studies
- Neuroendocrine regulation and behavior
- Neuroinflammation and Neurodegeneration Mechanisms
- Reproductive Health and Contraception
- Allergic Rhinitis and Sensitization
- Long-Term Effects of COVID-19
- Salivary Gland Disorders and Functions
- Obstructive Sleep Apnea Research
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Vestibular and auditory disorders
Charité - Universitätsmedizin Berlin
2019-2025
Humboldt-Universität zu Berlin
2023-2025
Freie Universität Berlin
2024-2025
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
2023
Background Switching between antibody classes might be a treatment option in migraine patients who have not responded to one class of CGRP-(receptor) monoclonal (mAb), but there are no efficacy data so far. In this real-world analysis, we assessed the response CGRP-mAb that previously failed CGRP-receptor-mAb erenumab. Methods We analyzed retrospective headache diary 78 with switched CGRP-mAbs at four German centers either due lack or intolerable side effects. Among these, identified 25 did...
Background: German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success at least five oral prophylactics or contraindications to such. In this real-world analysis we assessed treatment response chronic (CM) failed and, addition, onabotulinumtoxinA (BoNTA). Methods: We analyzed retrospective data of 139 CM one injection from two headache centers. Patients respond sufficiently had β-blockers, flunarizine, topiramate,...
National and international guidelines recommend stopping migraine prophylaxis with CGRP(-receptor) monoclonal antibodies after 6-12 months of successful therapy. In this study, we aimed to analyze the course for four cessation use.This longitudinal cohort study included patients who received a CGRP-(receptor) antibody ≥8 before treatment cessation. We analyzed headache data in four-week period prior mAb initiation (baseline), month last injection, weeks 5-8 13-16 treatment. Primary endpoint...
Clinical trials and real-world studies revealed a spectrum of response to CGRP(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at all total freedom. In this study, we aimed compare clinical characteristics between super-responders (SR) non-responders (NR) mAbs.We performed retrospective cohort study the Headache Center, Charité - Universitätsmedizin Berlin. The definition super-response was ≥ 75% reduction monthly headache days (MHD) third month after...
Sex hormones may modulate calcitonin gene-related peptide (CGRP) release in the trigeminovascular system. We studied CGRP concentrations plasma and tear fluid female participants with episodic migraine (EM) a regular menstrual cycle (RMC), EM combined oral contraception (COC), postmenopause. For control, we analyzed 3 corresponding groups of age-matched without EM.Participants an RMC had 2 visits: during menstruation on day ± periovulatory period 13 2. Participants COC were examined at 4...
Therapeutic options for migraine prevention in non-responders to monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are often limited. Real-world data have shown that the CGRP-receptor mAb erenumab may benefit from switching a CGRP ligand mAb. However, it remains unclear whether, vice versa, is effective mAbs. In this study, we aim assess efficacy of patients who previously failed mAb.This monocentric retrospective cohort study included with...
Migraine frequency increases after the cessation of successful preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs). In this study, we aimed to evaluate course migraine resumption.Patients migraine, who started same CGRP(-R) mAb a three-month drug holiday were included in analysis. We collected headache data at four prospective visits: 1) during weeks before initial (baseline); 2) last injection; 3) 13-16 holiday; 4) 9-12 restart. Outcomes changes monthly days (MMD), (MHD),...
Abstract Background To date, migraine is diagnosed exclusively based on clinical criteria, but fluid biomarkers are desirable to gain insight into pathophysiological processes and inform management. We investigated the state-dependent profile of for neuroaxonal damage microglial activation as two potentially relevant aspects in human pathophysiology. Methods This exploratory study included serum cerebrospinal (CSF) samples patients with during headache phase (ictally) ( n = 23), between...
Abstract Background Diagnosing headache disorders poses significant challenges, particularly in primary and secondary levels of care (PSLC), potentially leading to misdiagnosis underdiagnosis. This study evaluates diagnostic agreement for migraine, tension-type (TTH), cluster (CH) between PSLC tertiary (TLC) assesses adherence the International Classification Headache Disorders 3rd edition (ICHD-3) guidelines. Methods A retrospective, cross-sectional analysis was conducted at Charité -...
Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, high cost of these novel therapies has led to reimbursement policies requiring patients try multiple traditional preventives before access. In Germany, a recent change in insurance policy significantly expanded coverage CGRP receptor mAb erenumab, enabling who failed just one prior prophylactic medication receive this mAb. Here, we...
Abstract Objective Migraine, endometriosis, and the comorbidity of both are frequent pain disorders special relevance for women. The neuropeptide calcitonin gene‐related peptide (CGRP) is critically involved in migraine, circumstantial evidence suggests a role endometriosis. We assessed CGRP levels at different times menstrual cycle four groups: healthy women, women with migraine or endometriosis both. Methods Women episodic histologically confirmed were recruited from specialized centers....
Migraine and sleep disorders share a bidirectional relationship, but little is known about the specific association between migraine rapid eye movement (REM) behaviour disorder (RBD). The aim was to assess prevalence of RBD associated clinical characteristics in adults with migraine.
Migraine preventive treatment with CGRP(-receptor) monoclonal antibodies (mAbs) has a positive effect on patients' health-related quality of life (HRQoL). The German guidelines recommend discontinuing successful mAbs after 6-12 months. We aimed to evaluate headache-specific and generic HRQoL for three months discontinuation mAb treatment.We conducted prospective, longitudinal cohort study, including patients migraine 8-12 therapy CGRP(-R) before planned attempt. was assessed at the time last...
Abstract Background Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases can be influenced by neuropeptides such as CGRP, key neurotransmitter in migraine. Here, we report serum concentrations of total-tau migraine patients healthy controls. Methods In this cross-sectional study, interictal blood samples from n = 92 episodic (EM), 93 chronic (CM), 42 matched controls (HC) were studied. We assessed...
Discontinuation of treatment with monoclonal antibodies (mAb) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway leads to an increase in migraine frequency. We aimed assess changes free and total CGRP plasma concentrations after discontinuation CGRP(-receptor) mAbs. This prospective analysis included 59 patients (n = 25 erenumab, n galcanezumab, 9 fremanezumab) who discontinued mAbs ≥8 months treatment. Patients were visited at time last mAb injection (V1) 16 weeks later (V2). For...
Abstract Objective Alice in Wonderland Syndrome (AIWS) is a sensory disorder characterized by distorted somatosensory and/or visual perception. Additionally, distortion of time perception and symptoms derealization/depersonalization may occur. AIWS frequently associated with migraine. However, its prevalence, clinical characteristics remain poorly understood. Here, we investigated the prevalence features individuals We hypothesized more frequent migraine patients aura than those without...
Background Migraine patients unresponsive to calcitonin gene-related peptide (CGRP)(-receptor, -R) monoclonal antibodies (mAbs) may benefit from switching between CGRP(-R) mAbs. However, some do not tolerate or respond any subcutaneous This study evaluates the efficacy of intravenous CGRP mAb eptinezumab in these therapy-refractory patients. Methods In this retrospective cohort study, with migraine who previously failed erenumab and at least one (fremanezumab and/or galcanezumab) received...
Lockdown measures due to the COVID-19 pandemic have led lifestyle changes, which in turn may an impact on course of headache disorders. We aimed assess changes primary characteristics and factors during lockdown Germany using digital documentation mobile application (app) M-sense. analyzed data smartphone users, who entered daily app 28-day period before (baseline) first 28 days (observation period). This analysis included change monthly (MHD) observation compared baseline. also assessed...
Background Smartphone-based apps represent a major development in health care management. Specifically headache care, the use of electronic diaries via has become increasingly popular. In contrast to soaring volume available data, scientific these data resources is sparse. Objective this analysis, we aimed assess changes and migraine frequency, intensity, acute medication among people who showed daily diary as implemented freely basic version German commercial app, M-sense. Methods The...